Leaders in Partnering, M&A Deals and Strategic Alliances
What We Do
PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances. For the past 29 years, PharmaVentures has acted as advisor on over 900 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies worldwide.
PharmaVentures’ deep bank of specialist experience, deal analytics and network of contacts from innovators to large pharma makes us uniquely placed to support business in all aspects of deal making and strategic planning.
PharmaVentures is based in Oxford, UK, and employs over 20 professionals and has associates in Europe and Asia-Pacific.
For more information, download our corporate brochure.
Our Services
PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.
We have an experienced team of high-calibre professional advisors, business analysts and executives to provide and maintain the highest standards and full commitment to our clients, as well as dedicated professional support staff.
M&A
We support our clients with strategic advice and full end-to-end process management capabilities to derive optimum value from their M&A, divestments and strategic transactions, from identifying acquisition targets to advising on their exit strategy.
Licensing
Top tier pharmaceutical companies, biotechs, diagnostics, medtech, healthcare IT and life science research companies, universities and technology transfer agencies have trusted us to deliver the best licensing deals for their assets.
Fundraising
By entrusting the fundraising process to us, CEOs can concentrate on fulfilling their operational demands. We will ensure that the contractual terms reflect the spirit of the term sheet and subsequent negotiations. You are tapping into our experience and depth of knowledge gained from negotiating financing deals globally. We also provide Independent Expert Reports for IPOs.
Strategy
Using internal therapeutic expertise coupled with targeted data analytics, PharmaVentures works in collaboration with clients to develop actionable strategies to maximise their opportunity and mitigate risk.
Valuation & Positioning
We have valued assets across a wide range of different therapy areas such as CNS, Ophthalmology, Oncology, GI and Respiratory diseases. A number of major pharmaceutical companies have also relied upon our valuations for determining the outcome of a number of high profile contractual disputes.
PharmaVentures Expertise: Impactful Valuations
In deal making, how robust are your valuations?
PharmaVentures can give you confidence to negotiate the right financial terms for your companies, assets, & licensing deals, with vigorous valuations & impactful financial terms.
Watch this video to find out more.
Subscribe to our newsletter
For the latest industry news and thought leadership from our experts about life sciences M&A, licensing, fundraising, strategy, valuation and positioning, subscribe to our newsletter.
Thought Leadership
Latest News
PharmaVentures and Shinhan Investment Corp sign Memorandum of Understanding to strengthen global collaboration for the Korean biopharma industry
Oxford, UK, 18 November 2021 PharmaVentures is delighted to announce it has signed a Memorandum of Understanding (MOU) with the leading Korean investment bank, Shinhan Investment Corp Group &...
White Papers
Diagnostics
More important than ever, but there’s still a way to go. Just the other week, it was announced that Illumina had acquired GRAIL (subject to approval from the regulators), a company it formed in 2016...
PharmaVentures Insights
What is driving consolidation in the pharmaceutical contract services industry?
PharmaVentures partnered with Informa to deliver a live panel discussion during CPhI Worldwide in the form of a webinar.This webinar focuses on the future of broader outsourced contract services in...
Our Track Record
We conducted a detailed assessment of the market opportunities, technology risks and developments, launch and marketing costs via scenarios of “go-it-alone”, “outright sale”, “out-licensing for royalties” as well as “out-licensing with co-promotion”. The value generated was modelled and the scenarios were prioritised. Partnering and deal strategies were developed for the selected optimal strategy and incorporated into a business plan.
PharmaVentures developed a customised search strategy based on the specific requirements of the client, which involved a systemic country by country identification of candidates with the correct therapeutic indications, combined with their commercial potential and availability for the territories of interest.
PharmaVentures conducted a compound valuation (bottom-up and benchmarking using PharmaDeals Agreements® data) providing the basis for future negotiations. We also carried out a thorough company screening and evaluation assessment to identify and prioritise potential licensees. Following the screening, within the space of a month our transaction team approached all the target companies with a carefully constructed value proposition using a non-confidential information package.
Is ‘closed-shop’ innovation a threat of new therapies and the fate of some pharma?
by Dr Fintan Walton, CEO, PharmaVentures. After nearly 40 years in the pharmaceutical industry, I believe pharmaceutical companies have still not got it quite right when it comes to innovation In...
Meet Us
10-14 January 2022
BIO Partnering during JPM Week
17-19 January 2022
Biotech Showcase
28 February 2022
3rd Annual European HealthTech CEO Forum
Our Clients
What Our Clients Say
“I feel I made an excellent choice in PharmaVentures to serve as my exclusive advisors for the sale of the Company. They have a comprehensive understanding of our business and helped me identify the ideal partner that shared our strategic vision…I truly value the professional advice and the expert guidance made through every step of the process which enabled us to close the transaction to the satisfaction of all stakeholders.”